Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033904 · ClinicalTrials.gov registry record · Phase 3
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
A Phase 3 study of Renal Cell Carcinoma, sponsored by Agenus.
- Completed
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
- 20
- Study locations
NCT00033904 is a Phase 3 study of Renal Cell Carcinoma that has completed, run by Agenus. The registered enrollment target is 650 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT00033904, a Phase 3 study of Renal Cell Carcinoma, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
- 20
- Study locations
Study Summary
Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
Conditions Studied
Interventions
- DRUG autologous human tumor-derived HSPPC-96
Study Locations (20)
Florida
- - Boca Raton
- - Miami
- - Tampa
California
- - Los Angeles
- - San Francisco
Illinois
- - Chicago
- - Maywood
Alaska
- - Anchorage
Arizona
- - Tucson
Colorado
- - Denver
Connecticut
- - Farmington
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2000-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033904
The ClinicalTrials.gov registry entry for NCT00033904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (173% higher). The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which autologous human tumor-derived HSPPC-96 is the first listed.
NCT00033904 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00033904 about?
NCT00033904 is a clinical study titled "Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer". Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
What is the current status of trial NCT00033904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2000-06. Estimated completion is 2007-04.
What conditions does trial NCT00033904 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT00033904?
The interventions under investigation include: autologous human tumor-derived HSPPC-96 (DRUG).
Who is sponsoring clinical trial NCT00033904?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033904 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.